» Articles » PMID: 34480106

Polycythemia Vera: Historical Oversights, Diagnostic Details, and Therapeutic Views

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2021 Sep 4
PMID 34480106
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective 20-year rates of 26%, 16%, and 4%. Current treatment strategies in PV have not been shown to prolong survival or lessen the risk of leukemic or fibrotic progression and instead are directed at preventing thrombotic complications. In the latter regard, two risk categories are considered: high (age >60 years or thrombosis history) and low (absence of both risk factors). All patients require phlebotomy to keep hematocrit below 45% and once-daily low-dose aspirin, in the absence of contraindications. Cytoreductive therapy is recommended for high-risk or symptomatic low-risk disease; our first-line drug of choice in this regard is hydroxyurea but we consider pegylated interferon as an alternative in certain situations, including in young women of reproductive age, in patients manifesting intolerance or resistance to hydroxyurea therapy, and in situations where treatment is indicated for curbing phlebotomy requirement rather than preventing thrombosis. Additional treatment options include busulfan and ruxolitinib; the former is preferred in older patients and the latter in the presence of symptoms reminiscent of post-PV myelofibrosis or protracted pruritus. Our drug choices reflect our appreciation for long-term track record of safety, evidence for reduction of thrombosis risk, and broader suppression of myeloproliferation. Controlled studies are needed to clarify the added value of twice- vs once-daily aspirin dosing and direct oral anticoagulants. In this invited review, we discuss our current approach to diagnosis, prognostication, and treatment of PV in general, as well as during specific situations, including pregnancy and splanchnic vein thrombosis.

Citing Articles

Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification.

Thiele J, Kvasnicka H, Gianelli U, Arber D, Tefferi A, Vannucchi A Blood Cancer J. 2025; 15(1):31.

PMID: 40038244 PMC: 11880409. DOI: 10.1038/s41408-025-01235-7.


PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.

Yacoub A, Abu-Zeinah G, Qin A, Tashi T, Dana W, Shih W Ann Hematol. 2025; 104(1):335-345.

PMID: 39804351 PMC: 11868303. DOI: 10.1007/s00277-025-06185-5.


Hepcidin Is a Valuable Therapeutic Target for Colorectal Cancer.

Frascatani R, Colella M, Monteleone G Cancers (Basel). 2024; 16(23).

PMID: 39682254 PMC: 11640601. DOI: 10.3390/cancers16234068.


Practical guide for the diagnosis and treatment of localized and generalized cutaneous pruritus (chronic itch with no underlying pruritic dermatosis).

Hashimoto T, Okuno S J Dermatol. 2024; 52(2):204-220.

PMID: 39663861 PMC: 11807371. DOI: 10.1111/1346-8138.17565.


Arterial Stiffness as a New Predictor of Clinical Outcome in Patients with Polycythemia Vera.

Mulas O, Sestu A, Costa A, Chessa S, Vargiu C, Corda L J Clin Med. 2024; 13(22).

PMID: 39597955 PMC: 11595030. DOI: 10.3390/jcm13226811.


References
1.
DAMESHEK W . Some speculations on the myeloproliferative syndromes. Blood. 1951; 6(4):372-5. View

2.
Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

3.
James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

4.
Kralovics R, Passamonti F, Buser A, Teo S, Tiedt R, Passweg J . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-90. DOI: 10.1056/NEJMoa051113. View

5.
Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View